Mo W, Zhang JT. 2012. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol
3:1-27.
Morris JJ, Hughes LR, Glen AT, Taylor PJ. 1991. Non-steroidal antiandrogens. Design of novel compounds based on an
infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J Med
Chem 34:447-55.
Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. 2007. Phase I/II trial of a P-glycoprotein
inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients
with non-Hodgkin's lymphoma. Leuk Lymphoma 48:708-15.
Ohnmacht CJ, Russell K, Empfield JR, Frank CA, Gibson KH, Mayhugh DR, McLaren FM, Shapiro HS, Brown FJ, Trainor
DA, Ceccarelli C, Lin MM, Masek BB, Forst JM, Harris RJ, Hulsizer JM, Lewis JJ, Silverman SM, Smith RW, Warwick PJ,
Kau ST, Chun AL, Grant TL, Howe BB, Neilson KL, et al. 1996. N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides:
KATP potassium channel openers. Modifications on the western region. J Med Chem 39:4592-601.
Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. 2005. Tyrosine kinase inhibitor resistance in cancer: role of ABC
multidrug transporters. Drug Resist Updat 8:15-26.
Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh
CJ. 2008. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Drug Metab Dispos 36:695-701.
Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. 2000. Fumitremorgin C reverses multidrug resistance in
cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50.
Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE. 2003. Mutations at
amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-8.
Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE. 2001. A functional assay for detection of the
mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171-82.
Robey RW, Polgar O, Deeken J, To KW, Bates SE. 2007. ABCG2: determining its relevance in clinical drug resistance.
Cancer Metastasis Rev 26:39-57.
Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE. 2008. Inhibition of P-
glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally
administered inhibitor, CBT-1((R)). Biochem Pharmacol 75:1302-12.
Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW. 2006. Reversal of MDR1/P-
glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5:39-
47.
Shi Z, Tiwari AK, Patel AS, Fu LW, Chen ZS. 2011. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res
71:3735-8.
Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar
SV, Chen ZS. 2009. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Biochem Pharmacol 77:781-93.
Shukla S, Ohnuma S, Ambudkar SV. 2011. Improving cancer chemotherapy with modulators of ABC drug transporters.
Curr Drug Targets 12:621-30.
Shukla S, Sauna ZE, Ambudkar SV. 2008. Evidence for the interaction of imatinib at the transport-substrate site(s) of the
multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 22:445-7.
Sodani K, Patel A, Kathawala RJ, Chen ZS. 2012. Multidrug resistance associated proteins in multidrug resistance. Chin J
Cancer 31:58-72.
Stacy AE, Jansson PJ, Richardson DR. 2013. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol
Pharmacol 84:655-69.
Sun YL, Patel A, Kumar P, Chen ZS. 2012. Role of ABC transporters in cancer chemotherapy. Chin J Cancer 31:51-7.
Tiwari AK, Sodani K, Dai CL, Ashby CR, Jr., Chen ZS. 2011. Revisiting the ABCs of multidrug resistance in cancer
chemotherapy. Curr Pharm Biotechnol 12:570-94.
Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Jr., Chen X, Chen ZS. 2009. Nilotinib (AMN107, Tasigna) reverses
multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem
Pharmacol 78:153-61.
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro
through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-72.
Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. 2002. Overexpression of wild-type breast cancer resistance
protein mediates methotrexate resistance. Cancer Res 62:5035-40.
Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT, Chen ZS. 2014a.
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of
the ABCB1. Biochem Pharmacol 90:367-78.
Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. 2014b. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-
This article is protected by copyright. All rights reserved
15